Zenith Capital (Zenith Capital) Days Sales Outstanding : 0.00 (As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Days Sales Outstanding?

Zenith Capital's average Accounts Receivable for the three months ended in . 20 was $0.00 Mil. Zenith Capital's Revenue for the three months ended in . 20 was $0.00 Mil.

The historical rank and industry rank for Zenith Capital's Days Sales Outstanding or its related term are showing as below:

ZHCLF's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.545
* Ranked among companies with meaningful Days Sales Outstanding only.

Zenith Capital's Days Sales Outstanding stayed the same from . 20 (0.00) to . 20 (0.00).

Zenith Capital Days Sales Outstanding Historical Data

The historical data trend for Zenith Capital's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Days Sales Outstanding Chart

Zenith Capital Annual Data

Trend

Days Sales Outstanding

Zenith Capital Quarterly Data

Days Sales Outstanding

Competitive Comparison of Zenith Capital's Days Sales Outstanding

For the Biotechnology subindustry, Zenith Capital's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenith Capital's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Zenith Capital's Days Sales Outstanding falls into.

Zenith Capital Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Zenith Capital's Days Sales Outstanding for the fiscal year that ended in . 20 is calculated as

	Days Sales Outstanding (A: . 20 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: . 20 )	+	Accounts Receivable (A: . 20 ))	/	count )	/	Revenue (A: . 20 )	*	Days in Period
=	( (	+	)	/	1 )	/		*	365
=	0					/		*	365
=	N/A

Zenith Capital's Days Sales Outstanding for the quarter that ended in . 20 is calculated as:

	Days Sales Outstanding (Q: . 20 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: . 20 )	+	Accounts Receivable (A: . 20 ))	/	count )	/	Revenue (A: . 20 )	*	Days in Period
=	( (	+	)	/	1 )	/		*	365 / 4
=	0					/		*	365 / 4
=	N/A

Zenith Capital (OTCPK:ZHCLF) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Zenith Capital Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines